


Cervical Cancer Screening and Management Recommendations for Individuals 30^a to 65 Years of Age^b With a Cervix

[Click here for topics associated with this algorithm](#)



Abbreviations

ASC	American Cancer Society
ASC-US	Atypical squamous cells of undetermined significance
ASCCP	American Society for Colposcopy and Cervical Pathology
CIN2	Cervical squamous intraepithelial neoplasia 2
HPV	Human papillomavirus
hrHPV	High-risk HPV
LSIL	Low-grade squamous intraepithelial lesion
NAA	Nucleic acid amplification
NILM	Negative for intraepithelial lesion or malignancy

^aACS 2020 recommends screening according to these algorithms beginning at 25 years of age.
^bScreening is not recommended for individuals who are posthysterectomy with no history of cervical cancer or CIN2+.
^cACS 2020 prefers this option every 5 years beginning at age 25.
^dClient should retain aliquot for cytology testing in case of hrHPV positivity.
^eACS 2020 states that this is an acceptable option every 5 years, beginning at age 25, if FDA-approved primary HPV testing is unavailable.
^fACS 2020 states that this is an acceptable option every 3 years, beginning at age 25, if FDA- approved primary HPV testing is unavailable.

References

Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. *CA Cancer J Clin.* 2020;70(5):321-346.

Huh WK, Ault KA, Chelmow D, Davey DD, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *Gynecol Oncol.* 2015;136(2):178-182.

Massad S, Einstein MH, Huh WK, et al. 2012 ASCCP consensus guidelines conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *Obstet Gynecol.* 2013;121(4):829-846.

The American Society for Colposcopy and Cervical Pathology. [Cervical cancer screening recommendations, 2014](#). [Updated: Aug 2014; Accessed: Apr 2020]